Inhibition of liposome-induced complement activation by incorporated poly(ethylene glycol)-lipids.

Complement activation causes opsonization of foreign particles leading to particle elimination from the blood. Complement-mediated opsonization of charged and large liposomes presents a fundamental problem in their use to deliver therapeutic agents in vivo. To prolong the circulation half-lives of such liposomes, complement activation must be curtailed. The aim of this study was to assess the ability of poly(ethylene glycol)-lipids (PEG-lipids) to inhibit the in vitro activation of the classical pathway of complement in human serum by anionic liposomes. Incorporation of cholesterol-PEG600 (CH-PEG600), cholesterol-PEG1000 (CH-PEG1000), or phosphatidylethanolamine-PEG2000 (PE-PEG2000) resulted in dose-dependent inhibition of C1q binding and complement activation. The dose of PEG-lipid at which complement activation was blocked was inversely related to the PEG chain length. Complement activation was strongly inhibited when 15 mole% of CH-PEG600, 10 mole% CH-PEG1000, or 5 mole% PE-PEG2000 was incorporated into 100-nm anionic liposomes. PEG-lipid incorporation into larger liposomes (240 nm) was also successful in blocking C1q binding and complement activation. Radiolabeled cholesterol-PEG approximately 1400 was prepared and used to determine both the percentage of CH-PEG incorporated into the liposomes and the percentage maintained in the liposomes in the presence of 50% human serum at 37 degrees C for up to 24 h.

[1]  D. Devine,et al.  Liposome-complement interactions in rat serum: implications for liposome survival studies. , 1994, Biochimica et biophysica acta.

[2]  P. Lachmann,et al.  Lesions due to Complement in Lipid Membranes , 1971, Nature.

[3]  G Gregoriadis,et al.  Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly(ethylene glycol)-coated vesicles. , 1991, Biochimica et biophysica acta.

[4]  V. Torchilin,et al.  Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target. , 1991, Biochimica et biophysica acta.

[5]  G. Gregoriadis,et al.  Stability of small unilamellar liposomes in serum and clearance from the circulation: the effect of the phospholipid and cholesterol components. , 1982, Life sciences.

[6]  Devine,et al.  The complement system in liposome clearance: Can complement deposition be inhibited? , 1998, Advanced drug delivery reviews.

[7]  N. Van Rooijen,et al.  Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes. , 1994, Biochimica et biophysica acta.

[8]  D. Devine,et al.  The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. , 1991, Journal of immunology.

[9]  F. Davis,et al.  Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. , 1977, The Journal of biological chemistry.

[10]  K. Funato,et al.  The complement- but not mannose receptor-mediated phagocytosis is involved in the hepatic uptake of cetylmannoside-modified liposomes in situ. , 1994, Journal of drug targeting.

[11]  K. Matthay,et al.  Versatility in lipid compositions showing prolonged circulation with sterically stabilized liposomes. , 1992, Biochimica et biophysica acta.

[12]  C. H. Fiske,et al.  THE COLORIMETRIC DETERMINATION OF PHOSPHORUS , 1925 .

[13]  F. Kaudewitz,et al.  Electrophoretic pattern of and amino acid incorporation in vitro into the insoluble mitochondrial protein of neurospora crassa wild type and mi‐1 mutant , 1968, FEBS letters.

[14]  C. Alving,et al.  Cholesterol-dependent human complement activation resulting in damage to liposomal model membranes. , 1977, Journal of immunology.

[15]  P Couvreur,et al.  Complement consumption by poly(ethylene glycol) in different conformations chemically coupled to poly(isobutyl 2-cyanoacrylate) nanoparticles. , 1997, Life sciences.

[16]  K. Funato,et al.  Contribution of complement system on destabilization of liposomes composed of hydrogenated egg phosphatidylcholine in rat fresh plasma. , 1992, Biochimica et biophysica acta.

[17]  P. Cullis,et al.  Poly(ethylene glycol)--lipid conjugates regulate the calcium-induced fusion of liposomes composed of phosphatidylethanolamine and phosphatidylserine. , 1996, Biochemistry.

[18]  A. Gabizon,et al.  The role of surface charge and hydrophilic groups on liposome clearance in vivo. , 1992, Biochimica et biophysica acta.

[19]  R L Juliano,et al.  The effect of particle size and charge on the clearance rates of liposomes and liposome encapsulated drugs. , 1975, Biochemical and biophysical research communications.

[20]  S. Pizzo,et al.  A new procedure for the synthesis of polyethylene glycol-protein adducts; effects on function, receptor recognition, and clearance of superoxide dismutase, lactoferrin, and alpha 2-macroglobulin. , 1983, Analytical biochemistry.

[21]  J. Tschopp,et al.  Antibody-independent activation of C1, the first component of complement, by cardiolipin. , 1985, Journal of immunology.

[22]  J. M. Harris,et al.  Poly(Ethylene Glycol) Chemistry Biotechnical and Biomedical Applications , 1992 .

[23]  K. Maruyama,et al.  Prolonged circulation time in vivo of large unilamellar liposomes composed of distearoyl phosphatidylcholine and cholesterol containing amphipathic poly(ethylene glycol). , 1992, Biochimica et biophysica acta.

[24]  D. Devine,et al.  Liposome-induced activation of the classical complement pathway does not require immunoglobulin. , 1994, Biochimica et biophysica acta.

[25]  Buddy D. Ratner,et al.  Polymers as Biomaterials , 1999 .

[26]  T. Allen,et al.  Effect of liposome size and drug release properties on pharmacokinetics of encapsulated drug in rats. , 1983, The Journal of pharmacology and experimental therapeutics.

[27]  B. Wines,et al.  Enhancement of the binding of C1q to immune complexes by polyethylene glycol. , 1988, Molecular immunology.

[28]  H. Yoshioka.  Surface modification of haemoglobin-containing liposomes with polyethylene glycol prevents liposome aggregation in blood plasma. , 1991, Biomaterials.

[29]  N. Cooper,et al.  Purification and radiolabeling of human C1q. , 1981, Journal of immunology.

[30]  J. Baldeschwieler,et al.  The pharmacological efficacy of a rigid non-phospholipid liposome drug delivery system. , 1984, Biochimica et biophysica acta.

[31]  C. Alving,et al.  Complement-dependent phagocytosis of liposomes. , 1993, Chemistry and physics of lipids.

[32]  L. Huang,et al.  Amphipathic poly(ethylene glycol) 5000-stabilized dioleoylphosphatidylethanolamine liposomes accumulate in spleen. , 1992, Biochimica et biophysica acta.

[33]  W. Rodrigueza.  Studies on the antiatherogenic properties of liposomes , 1994 .

[34]  P. Cullis,et al.  Factors influencing the retention and chemical stability of poly(ethylene glycol)-lipid conjugates incorporated into large unilamellar vesicles. , 1994, Biochimica et biophysica acta.

[35]  P. Cullis,et al.  Influence of dose on liposome clearance: critical role of blood proteins. , 1996, Biochimica et biophysica acta.

[36]  G Blume,et al.  Molecular mechanism of the lipid vesicle longevity in vivo. , 1993, Biochimica et biophysica acta.

[37]  M. Bally,et al.  Production of large unilamellar vesicles by a rapid extrusion procedure: characterization of size distribution, trapped volume and ability to maintain a membrane potential. , 1985, Biochimica et biophysica acta.

[38]  T. Allen,et al.  Uptake of liposomes by cultured mouse bone marrow macrophages: influence of liposome composition and size. , 1991, Biochimica et biophysica acta.

[39]  M. Bally,et al.  Liposomes with entrapped doxorubicin exhibit extended blood residence times. , 1990, Biochimica et biophysica acta.

[40]  J. Silvius,et al.  Interbilayer transfer of phospholipid-anchored macromolecules via monomer diffusion. , 1993, Biochemistry.

[41]  K. Miyajima,et al.  Binding and uptake of liposomes containing a poly(ethylene glycol) derivative of cholesterol (stealth liposomes) by the macrophage cell line J774: influence of PEG content and its molecular weight. , 1996, Biochimica et biophysica acta.

[42]  M. Bally,et al.  Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. , 1989, Cancer research.

[43]  T M Allen,et al.  Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. , 1991, Biochimica et biophysica acta.

[44]  D. Brooks,et al.  Interfacial thickness of liposomes containing poly(ethylene glycol)-cholesterol from electrophoresis. , 1996, Biophysical journal.

[45]  G Blume,et al.  Liposomes for the sustained drug release in vivo. , 1990, Biochimica et biophysica acta.

[46]  Dexi Liu,et al.  Recognition and clearance of liposomes containing phosphatidylserine are mediated by serum opsonin. , 1995, Biochimica et biophysica acta.